COVID-19: A trigger of autoimmune diseases

Area of Science:

• Immunology
• Virology
• Pathology

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a global health emergency.
• Viral entry into host cells involves interaction between the SARS-CoV-2 S protein and angiotensin-converting enzyme 2 (ACE2).
• Effective immune responses, encompassing innate and adaptive immunity, are crucial for controlling SARS-CoV-2 infection.

Purpose of the Study:

• To review the association between COVID-19 and the development of autoimmune disorders.
• To explore the potential mechanisms linking SARS-CoV-2 infection to immune system hyperactivity and autoantibody production.

Main Methods:

• Literature review of studies investigating COVID-19 and autoimmune conditions.
• Analysis of the immunological mechanisms underlying post-COVID-19 autoimmune manifestations.

Main Results:

• COVID-19 can lead to immune system hyperactivity, characterized by a "cytokine storm" and acute respiratory distress syndrome.
• Post-SARS-CoV-2 infection, immune hyperactivity and autoantibody production are associated with various autoimmune diseases, including autoimmune hemolytic anemia, autoimmune thrombocytopenia, Guillain-Barré syndrome, vasculitis, multiple sclerosis, pro-thrombotic states, and diffuse coagulopathy.
• Autoinflammatory conditions like Kawasaki disease in children have also been linked to COVID-19.

Conclusions:

• COVID-19 poses a significant risk for triggering or exacerbating autoimmune and autoinflammatory conditions.
• Understanding the immunopathology of COVID-19 is critical for managing its long-term sequelae, including autoimmune manifestations.
• Further research is warranted to elucidate the precise mechanisms and develop targeted therapeutic strategies for post-COVID-19 autoimmune disorders.